Atea Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AVIR research report →
Range $7 – $7
Price Chart
About the company
Atea Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV).
- CEO
- Jean-Pierre Sommadossi
- IPO
- 2020
- Employees
- 55
- HQ
- Boston, MA, US
Get TickerSpark's AI analysis on AVIR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $318.00M
- P/E
- -1.99
- PEG
- 0.18
- P/S
- 0.00
- P/B
- 1.78
- EV/EBITDA
- -1.33
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -69.92%
- ROIC
- -93.80%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-180,887,000
- Net Income
- $-158,349,000+6.0%
- EPS
- $-1.94+3.0%
- OCF Growth
- +2.6%
- FCF Growth
- +2.6%
- 52W High
- $6.45
- 52W Low
- $2.92
- 50D MA
- $4.68
- 200D MA
- $4.95
- Beta
- 0.28
- RSI (14)
- 37
- Avg Volume
- 287.37K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Atea reported positive Phase 3 HCV data, advanced its HEV program, and said its new debt facility extends runway into mid-2028 while it prepares for 2027 regulatory and clinical milestones.· November 9, 2026
- C-BEYOND met its primary endpoint with 94% SVR for BEM/RZR versus 95% for sofosbuvir-velpatasvir, achieving non-inferiority within the 5% margin.
- The company said C-FORWARD remains on track for top-line results in early 2027, with NDA submission targeted for mid-2027 if the data are positive.
- AT-587 completed the single-ascending-dose portion of Phase 1, and Atea expects proof-of-concept work in the first half of 2027 with preliminary results late 2027.
- Atea ended the quarter with $191.2 million in cash and marketable securities and drew $65 million at closing from a new Hercules credit facility that can reach $200 million.
- Management emphasized commercial planning for an anticipated 2028 U.S. launch, including payer research, manufacturing readiness, and a focused sales force plan.
Atea reported cash and marketable securities of $191.2 million as of 9/30/2026. In C-BEYOND, BEM/RZR achieved a 94% SVR rate versus 95% for sofosbuvir-velpatasvir in the primary MITT population, meeting non-inferiority within the prespecified 5% margin; in non-cirrhotic patients, BEM/RZR achieved 94% SVR versus 95%, and in compensated cirrhosis both arms achieved 95% SVR. Safety was described as comparable, with no serious adverse events due to study drugs and no early discontinuations related to study drugs. For guidance, Atea expects C-FORWARD top-line results in early 2027, NDA submission targeted for mid-2027 pending positive data, AT-587 proof-of-concept in the first half of 2027 with preliminary results late 2027, and the Hercules facility to fund planned operations into mid-2028; management also said the facility should be sufficient to support the commercial launch and alleviate the need for equity financing.
Jean-Pierre Sommadossi said the quarter marked significant progress across the pipeline and set the stage for a milestone-rich 2027. He framed BEM/RZR as a potential best-in-class HCV regimen and AT-587 as a potential first-in-class HEV therapy, highlighting the company’s goal of addressing serious viral diseases with differentiated treatments. His tone was constructive and forward-looking, emphasizing the company’s readiness for commercialization and the importance of the upcoming clinical and regulatory readouts.
Andrea Corcoran said Atea had $191.2 million in cash and investments at 9/30/2026 and that spending in the third quarter was mainly directed to C-BEYOND and C-FORWARD, with some spend on AT-587 startup activities. She said R&D spending fell in the first nine months of 2026 due to lower external HCV phase 3 spend, partly offset by HEV-related preclinical and clinical activity, while G&A declined due to lower salaries, stock-based compensation, and professional fees. On the new Hercules credit facility, she said Atea received $65 million at closing on November 6, that the $200 million facility should fund planned operations into mid-2028, and that the facility could extend cash runway through profitability if the U.S. launch succeeds and spending stays consistent with current plans.
Analysts asked about payer discussions, commercial channel mix, and whether Atea would need equity financing for launch. Management said it has not yet entered payer discussions because it is too early without an approved product, but it is evaluating the market landscape now; it also said roughly half of the U.S. HCV market is Medicaid and the rest is split between Medicare and commercial coverage. On funding, management said the $200 million credit facility would be more than sufficient for launch and would alleviate the need for equity financing. Management also said the pending HCV elimination bill is unlikely to move forward in the new Congress and would need to be reintroduced.
The main bull case from the call is that Atea now has positive Phase 3 efficacy data in hand for C-BEYOND and another readout ahead in early 2027, keeping the HCV program on a clear regulatory path. Management also stressed a differentiated profile for BEM/RZR—shorter duration, low drug-interaction risk, and no food effect—plus a financing package that extends runway into mid-2028 and supports commercialization planning.
The biggest risks are that the company still needs a successful C-FORWARD readout and a positive regulatory path before launch, so the HCV thesis is not yet de-risked. Management also acknowledged it has not started payer negotiations, the HCV elimination bill may not advance, and the commercial opportunity depends on execution in a market where treatment dynamics and government coverage changes remain fluid.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 75.5%
- Shares Outstanding
- 80.30M
- Float Shares
- 60.63M
of shares held by institutions
127 13F filers
Buy/sell ratio 0.45. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 12.03M | ▲ 26.64K |
| Blackrock, Inc. | 9.06M | ▲ 341.45K |
| Bml Capital Management, LLC | 6.75M | ▼ 198.67K |
| Tang Capital Management LLC | 4.81M | 0 |
| Vanguard Group Inc | 4.23M | ▼ 482.17K |
| Vanguard Capital Management LLC | 2.91M | ▼ 58.07K |
| Acadian Asset Management LLC | 2.34M | ▲ 303.08K |
| Bain Capital Life Sciences Investors, LLC | 2.08M | 0 |
| Geode Capital Management, LLC | 1.91M | ▼ 48.15K |
| State Street Corp | 1.63M | ▼ 25.46K |
| Two Sigma Investments, LP | 1.30M | ▼ 203.36K |
| Dimensional Fund Advisors LP | 1.30M | ▲ 809 |
Held by 169 ETFs
Biggest fund positions in AVIR by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 19, 26 | Lucidi Bruno | other | 53,372 |
| Nov 19, 26 | Lucidi Bruno | sell | 22,619 |
| Nov 17, 26 | Lucidi Bruno | other | 21,628 |
| Nov 17, 26 | Lucidi Bruno | sell | 6,741 |
| Nov 17, 26 | Lucidi Bruno | other | 21,628 |
| Nov 19, 26 | Lucidi Bruno | other | 53,372 |
| Nov 19, 26 | Polsky Bruce | sell | 8,750 |
| Nov 18, 26 | Polsky Bruce | other | 18,252 |
| Nov 16, 26 | Polsky Bruce | other | 48,028 |
| Nov 17, 26 | Polsky Bruce | other | 8,720 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AVIR coverage
Recent articles, reports, and earnings notes.

Nordicus Partners IPO: What Investors Need to Know
Nordicus Partners Corporation (NASDAQ: NORD) is expected to list on 2026-10-30, but the company has not disclosed a price range yet. The story is less a classic IPO and more a microcap biotech holding-company setup tied to Nordic life sciences assets. Bull case: asset-backed biotech optionality; bear case: no disclosed terms, nominal revenue, and going-concern risk.

What to Watch as Alopexx, Inc. Prices Its NASDAQ IPO
Alopexx, Inc. (ALPX) is expected to list on NASDAQ on 2026-07-07, but the company has not disclosed a price range or share count yet. The setup is a binary biotech story: broad anti-infective science with a small cash base, but a long path to pivotal data and more capital.
Want a deeper read on AVIR?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Atea Pharmaceuticals: A Clean DDI Profile And Shorter Treatment Duration Threaten Current Market Leaders
seekingalpha.com · Nov 13
Atea Pharmaceuticals, Inc. (AVIR) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 10
What Atea Pharmaceuticals (AVIR) Said on Its Q3 Earnings Call
marketbeat.com · Nov 9
Atea Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
globenewswire.com · Nov 9
Atea Pharmaceuticals Secures Credit Facility for Up to $200 Million from Hercules Capital
globenewswire.com · Nov 9
Atea Pharmaceuticals to Host Third Quarter 2026 Financial Results and Business Update Conference Call on November 9, 2026
globenewswire.com · Nov 2
Atea Pharmaceuticals, Inc. (AVIR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
seekingalpha.com · Sep 15
Atea Pharmaceuticals to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
globenewswire.com · Sep 8
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.